Related Experiment Video
Updated: Mar 6, 2026

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
Roles of RUNX in Hippo Pathway Signaling
Antonino Passaniti1, Jessica L Brusgard2, Yiting Qiao3
1Department of Pathology and Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, and the Veterans Administration Health Service, Baltimore, MD, USA. TPassaniti@som.umaryland.edu.
Abstract:
The Runt-domain (RD) transcription factors (RUNX genes) are an important family of transcriptional mediators that interact with a variety of proteins including the Hippo pathway effector proteins, YAP and TAZ. In this chapter we focus on two examples of RUNX-TAZ/YAP interactions that have particular significance in human cancer. Specifically, recent evidence has found that RUNX2 cooperates with TAZ to promote epithelial to mesenchymal transition mediated by the soluble N-terminal ectodomain of E-Cadherin, sE-Cad. Contrastingly, in gastric cancer, RUNX3 acts as a tumor suppressor via inhibition of the YAP-TEAD complex and disruption of downstream YAP-mediated gene transcription and the oncogenic phenotype. The reports highlighted in this chapter add to the growing repertoire of instances of Hippo pathway crosstalk that have been identified in cancer. Elucidation of these increasingly complex interactions may help to identify novel strategies to target Hippo pathway dysregulation in human cancer.
Insights
Runt-domain (RD) transcription factors like RUNX2 and RUNX3 interact with Hippo pathway proteins YAP and TAZ. These interactions play dual roles in cancer, promoting or suppressing tumor growth depending on the specific RUNX gene and cancer type.
Area of Science:
- Molecular Biology
- Cancer Biology
- Cell Signaling
Background:
- Runt-domain (RD) transcription factors (RUNX genes) are crucial mediators interacting with Hippo pathway proteins YAP and TAZ.
- Dysregulation of the Hippo pathway and RUNX factors is implicated in human cancers.
- Understanding these interactions is key to developing targeted cancer therapies.
Purpose of the Study:
- To explore the significance of RUNX-TAZ/YAP interactions in human cancer.
- To highlight contrasting roles of RUNX family members in cancer progression.
- To identify novel therapeutic strategies targeting Hippo pathway crosstalk in cancer.
Main Methods:
- Review of recent scientific literature on RUNX-TAZ/YAP interactions.
- Analysis of specific examples of RUNX2 and RUNX3 involvement in cancer.
- Focus on epithelial to mesenchymal transition and tumor suppression mechanisms.
Main Results:
- RUNX2 cooperates with TAZ to promote epithelial to mesenchymal transition via sE-Cad.
- RUNX3 functions as a tumor suppressor in gastric cancer by inhibiting YAP-TEAD complex.
- These findings illustrate Hippo pathway crosstalk with RUNX factors in cancer.
Conclusions:
- RUNX-TAZ/YAP interactions exhibit context-dependent roles in human cancer.
- RUNX2 and RUNX3 present opposing functions in cancer progression.
- Further elucidation of these complex interactions may reveal new therapeutic targets for cancer treatment.
Related Concept Videos
Hedgehog Signaling Pathway
Regulation of Angiogenesis and Blood Supply
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Lineage Commitment

